OBJECTIVE: To evaluate the prognostic value of the tumour stroma ratio (TSR) in resected adenocarcinoma of the oesophagus. BACKGROUND: In the literature, a refinement of oesophageal cancer staging has been proposed. Recently, TSR has been identified as a histological characteristic of the tumour itself that proved to be a strong predictor for survival in colorectal cancer. METHODS: In our cancer registry database, we identified 93 consecutive patients who underwent resection for oesophageal adenocarcinoma between 1990 and 2004 in two hospitals in our region. Using a predefined histopathological protocol, TSR was determined on the original haematoxylin-eosin (H&E) tissue sections of oesophagectomy specimens by two independent investigators. RESULTS: With a cut-off value of 50% tumour/stroma, patients were classified as TSR high (n=60) or TSR low (n=33). There were no significant differences in patient, tumour and treatment characteristics between the two groups, except for M status (M1a) and radicality of resection. The (disease-free) survival in the TSR high group was significantly better than in the TSR low group. By multivariate analysis, TSR was identified as a highly significant prognostic factor for overall survival (HR 2.0; P=0.010), independent of depth of tumour invasion, nodal status, lymph node ratio, extracapsular involvement, TNM stage, histological grade and radicality of resection. CONCLUSION: TSR is a new and practicable prognostic tumour characteristic for oesophageal adenocarcinoma that can discriminate patients with a poor outcome from those with a better outcome. Copyright 2009 Elsevier Ltd. All rights reserved.
OBJECTIVE: To evaluate the prognostic value of the tumour stroma ratio (TSR) in resected adenocarcinoma of the oesophagus. BACKGROUND: In the literature, a refinement of oesophageal cancer staging has been proposed. Recently, TSR has been identified as a histological characteristic of the tumour itself that proved to be a strong predictor for survival in colorectal cancer. METHODS: In our cancer registry database, we identified 93 consecutive patients who underwent resection for oesophageal adenocarcinoma between 1990 and 2004 in two hospitals in our region. Using a predefined histopathological protocol, TSR was determined on the original haematoxylin-eosin (H&E) tissue sections of oesophagectomy specimens by two independent investigators. RESULTS: With a cut-off value of 50% tumour/stroma, patients were classified as TSR high (n=60) or TSR low (n=33). There were no significant differences in patient, tumour and treatment characteristics between the two groups, except for M status (M1a) and radicality of resection. The (disease-free) survival in the TSR high group was significantly better than in the TSR low group. By multivariate analysis, TSR was identified as a highly significant prognostic factor for overall survival (HR 2.0; P=0.010), independent of depth of tumour invasion, nodal status, lymph node ratio, extracapsular involvement, TNM stage, histological grade and radicality of resection. CONCLUSION: TSR is a new and practicable prognostic tumour characteristic for oesophageal adenocarcinoma that can discriminate patients with a poor outcome from those with a better outcome. Copyright 2009 Elsevier Ltd. All rights reserved.
Authors: Sophie C Hagenaars; Kiki M H Vangangelt; Gabi W Van Pelt; Zsófia Karancsi; Rob A E M Tollenaar; Andrew R Green; Emad A Rakha; Janina Kulka; Wilma E Mesker Journal: Breast Cancer Res Treat Date: 2022-04-16 Impact factor: 4.624
Authors: W E Mesker; T J A Dekker; E M de Kruijf; C C Engels; G W van Pelt; V T H B M Smit; R A E M Tollenaar Journal: Br J Cancer Date: 2014-11-13 Impact factor: 7.640
Authors: C L Downey; S A Simpkins; D L Holliday; J L Jones; L B Jordan; J Kulka; A M Hanby; V Speirs Journal: Br J Cancer Date: 2014-11-13 Impact factor: 7.640
Authors: Amanda Eustace; Joely J Irlam; Janet Taylor; Helen Denley; Shailesh Agrawal; Ananya Choudhury; David Ryder; Jonathan J Ord; Adrian L Harris; Ana M Rojas; Peter J Hoskin; Catharine M L West Journal: Radiother Oncol Date: 2013-06-14 Impact factor: 6.280
Authors: Hannah Panayiotou; Nicolas M Orsi; Helene H Thygesen; Alexander I Wright; Matthew Winder; Richard Hutson; Michele Cummings Journal: BMC Cancer Date: 2015-12-16 Impact factor: 4.430